In-vitro Toxicology Testing Market Demand, Size, Report to 2032
The global in-vitro toxicology testing market size was exhibited at USD 29.19 billion in 2022 and is projected to hit around USD 76.47 billion by 2032, growing at a CAGR of 10.11% during the forecast period 2023 to 2032.
Key Pointers:
In-vitro Toxicology Testing Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 32.14 Billion |
|
Market Size by 2032 |
USD 76.47 Billion |
|
Growth Rate From 2023 to 2032 |
CAGR of 10.11% |
|
Base Year |
2022 |
|
Forecast Period |
2023 to 2032 |
|
Segments Covered |
Technology, application, method, end-user |
|
Market Analysis (Terms Used) |
Value (US$ Million/Billion) or (Volume/Units) |
|
Regional Scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key Companies Profiled |
Charles River Laboratories International, Inc.; SGS S.A.; Merck KGaA; Eurofins Scientific; Abbott Laboratories; Laboratory Corporation of America Holdings; Evotec S.E.; Thermo Fisher Scientific, Inc.; Quest Diagnostics Incorporated; Agilent Technologies, Inc.; Catalent, Inc.; Danaher Corporation; Bio-Rad Laboratories, Inc.; BioIVT; Gentronix |
Over the years, acceptance of in-vitro toxicology testing methods by regulatory authorities is increasing at a faster pace & thus validation of these tests methods opposed to conventional testing is even rising. Also, development of technologies to substitute animal use for toxicology tests has fueled the usage of in-vitro models such as in-silico simulation, assays, 3D cell cultures and many more, thereby boosting market growth.
Screening of a new drug candidate involves the use of animals for preclinical studies which is very tedious and expensive. However, in recent times, several jurisdictions are promoting ban for animal-based chemical testing. For example, for several years, the EU has been promoting the reduction, replacement, and refinement of animal tests. The Regulation on cosmetic products (1223/2009), REACH (2007/2006), the Directive on the protection of animals used for scientific purposes (2010/63), and Classification, Labelling and Packaging (CLP) (1272/2008) are some examples of EU legislation that are engaged in strongly encouraging the replacement of animal toxicology testing. Furthermore, in June 2018, the Cruelty-Free Cosmetics Act was passed in California to ban the selling of animal-tested products after 2020.
Many governments and private organization are taking actions to minimize conventional testing models, providing funds to support & develop in-vitro toxicology assays and form conducive government policies. Thus, increase in government initiatives that are focused on banning animal testing can be attributed to the rise in adoption of in-vitro toxicological models and creates many opportunities within the market. For instance, approximately USD 3.2 million were contributed by People for the Ethical Treatment of Animals (PETA) and its international associates to promote the development of non-animal test methods.
The advancements in computational and screening methods such as biological, high throughput, and chemical coupled with the vast number of public databases for toxicity analysis has expanded largely. This has allowed researchers to access information for drug discovery studies, toxicology profiling, and drug development programs. For instance, the MetaTox HS project by Agilent Technologies, Inc. brings advanced solutions for toxicity assays & high sensitivity metabolism during drug development procedures.
Technology Insights
The cell culture technology segment held the highest market share of 43.18% in 2022. As cell cultures provide reproducible results to consistent samples, they serve as excellent models for toxicology assays. This further enables early stage drug toxicity testing due to which this technology is gaining popularity & extensive application. Moreover, cell culturing technology is adopted in comparison to animal testing by healthcare academic institutions, biotechnology industries, and pharmaceutical manufacturers across the globe.
There has been rising adoption of high throughput technologies (HTTs) in the pharmaceutical industry and this can be attributed for the highest growth rate of this segment. The increase in need for reducing toxicity failure burden along with multiple drugs in product pipeline will contribute to the growth during the forecast.as the attrition rate for the drugs due to toxicity in clinics have not declined.Furthermore, incorporation of HTT in vitro models aids in examining varied dose levels, chemicals, and their effects. Researchers are keen on making use of such data to carry out predictive analysis.
Application Insights
The systemic toxicology segment captured the largest market share of 67.19% in 2022 and anticipated to witness the fastest growth during 2023 - 2032. Owing to the understanding of adverse reactions that occurs in relatively short time after drug administration will drive the adoption of this segment in the market.There are various types of systemic toxicology studies which includes acute systemic toxicity, sub-acute systemic toxicity, sub-chronic systemic toxicity and chronic systemic toxicity. Hence, the goal is to generate a precise data points like- minimum dose that results in toxicity, maximum tolerated dose, plasma concentration which leads to toxicity and margin of safety which is used to make decisions.
Similarly, the dermal toxicity segment will also witness significant CAGR during the forecasted years. In-vitro toxicology assays for assessing dermal toxicity are much simple, cost-reliable and effective rather than animal testing. The regulatory framework for toxicity tests of cosmetics is also driving the demand for in-vitro dermal toxicity testing. In the current scenario many countries like Israel, Norway, Brazil and India are following the suit with the ban which was been introduced in Europe. Government which could ban testing of cosmetics on animals can also ban the sale of cosmetics that are tested on animals. Besides, the advancements in in-vitro tools for risk assessment during dermal toxicity will also fuel growth in the market.
Method Insights
The cellular assay segment captured the largest market share of 44.15% in 2022. As cell cultures are excellent models and are available widely for analyzing the pharmacokinetic profile of drugs, cellular assays attribute to the high revenue in in-vitro toxicology testing market. Furthermore, early stage drug toxicity profiling also contributes to this segment’s revenue and drives its growth.
Cellular assays as in-vitro models offer several benefits such as speed of analysis, minimum cost, and even potential technological advances such as automation. In addition, key efforts laid down by manufacturers for the development of novel cellular assays will also boost the market progression during the forecast. For instance, Enzo Life Sciences provides a board range of fluorescence-based live cell assays, CELLESTIAL, that are capable of investing cell biology and its interconnection with disease pathology.
In-silico analysis for toxicology testing will also expand at a significant CAGR during the 2023 -2032 period. Implementation of analysis strategy via computational tools for safety assessment in an informed and efficient manner will propel the product development during all stages. This technological development will create new market opportunities & result in higher demand in the toxicology testing industry.
End-user Insights
In 2022, the pharmaceutical industry segment held the highest share of 42.9% in the market. It is attributed to the high use of toxicology testing for analyzing the pharmacokinetic properties of pharmaceutical drugs. Both novel and generic drugs require assays for toxicology testing. Areas such as absorption, distribution, metabolism, and excretion (ADME), genotoxicity, safety pharmacology necessitate the use of toxicity assays. Additionally, the continuous development and research for new drugs coupled with candidate drug pipeline will propel the demand for in-vitro testing methods.
The diagnostics segment is estimated to witness the fastest growth rate during the forecast due to rising number of diagnostic devices. The COVID-19 pandemic also pushed the diagnostic segment to develop innovative solutions for virus detection. Moreover, companies provide a comprehensive diagnostics product line for detection of therapeutic drug monitoring, long-term alcohol abuse, and point-of-care drug testing, thereby boosting the segment growth.
Regional Insights
North America held the largest revenue share of 47.11% in market during 2022. Owing to the rising government funding for research of therapeutics, increased healthcare expenditure, advanced infrastructure & processes for drug discovery and strong regulatory framework for approval has increased the demand as well as adoption on in-vitro testing methods in this region’s market.
Furthermore, launch of biologics by biopharmaceutical players in North America, particularly the U.S. has driven the adoption of toxicology testing and will contribute to future revenue generation. Presence of multiple government & private agencies for funding programs will also contribute to the fastest growth rate in 2023-2032.
On the other hand, Asia Pacific will also register significant CAGR during the forecast period due to development of health care settings, increased geriatric population in need of medicines, and various government incentives for enhancing technology and development.
Some of the prominent players in the In-vitro Toxicology Testing Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global In-vitro Toxicology Testing market.
By Technology
By Application
By Method
By End-user
By Region
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.2 In-vitro Toxicology Testing Market: Cost Structure Analysis
3.3 Market Trends & Outlook
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Rise In Government Funding For Toxicology Research
3.4.1.2 Opposition To Animal Testing
3.4.1.3 Ongoing Developments To Adavnce Toxicology Research
3.4.2 Market Restraint Analysis
3.4.2.1 Lack of in-vitro models
3.4.2.2 Issues pertaining to standarization of in-vitro studies
3.5 Penetration &Growth Prospect Mapping, 2022
3.6 In-vitro Toxicology Testing Market - Porter’s Analysis
3.7 In-vitro Toxicology Testing Market - SWOT Analysis
3.8 COVID-19 Impact Analysis
Chapter 4 End-user Business Analysis
4.1 In-vitro Toxicology Testing Market: End-user Movement Analysis
4.2 Pharmaceutical Industry
4.2.1 In-Vitro Toxicology Market For Pharmaceutical Industry, 2020 - 2032
4.3 Cosmetics & Household Products
4.3.1 In-Vitro Toxicology Market For Cosmetics And Household Products, 2020 - 2032
4.4 Academic Institutes & Research Laboratories
4.4.1 In-Vitro Toxicology Market For Academic Institutes & Research Laboratories, 2020 - 2032
4.5 Diagnostics
4.5.1 In-Vitro Toxicology Market For Diagnostics, 2020 - 2032
4.6 Chemicals Industry
4.6.1 In-Vitro Toxicology Market For Chemicals Industry, 2020 - 2032
4.7 Food Industry
4.7.1 In-Vitro Toxicology Market For Food Industry, 2020 - 2032
Chapter 5 Technology Business Analysis
5.1 Global In Vitro Toxicology Testing Market: Technology Movement Analysis
5.2 Cell Culture Technology
5.2.1 In-Vitro Toxicology Market For Cell Culture Technology, 2020 - 2032
5.3 High-Throughput Technology (Htt)
5.3.1 In-Vitro Toxicology Market For Htt, 2020 - 2032
5.4 Molecular Imaging
5.4.1 In-Vitro Toxicology Market For Molecular Imaging, 2020 - 2032
5.5 Omics Technology
5.5.1 In-Vitro Toxicology Market For Omics Technology, 2020 - 2032
Chapter 6 Application Business Analysis
6.1 In-Vitro Toxicology Testing Market: Application Movement Analysis
6.2 Systemic Toxicology
6.2.1 In-Vitro Toxicology Market For Systemic Toxicology, 2020 - 2032
6.3 Dermal Toxicity
6.3.1 In-Vitro Toxicology Market For Dermal Toxicity, 2020 - 2032
6.4 Endocrine Disruption
6.4.1 In-Vitro Toxicology Market For Endocrine Disruption, 2020 - 2032
6.5 Ocular Toxicity
6.5.1 In-Vitro Toxicology Market For Ocular Toxicity, 2020 - 2032
6.6 Other Applications
6.6.1 In-Vitro Toxicology Market For Other Applications, 2020 - 2032
Chapter 7 Method Business Analysis
7.1 Global In Vitro Toxicology Testing Market: Method Movement Analysis
7.2 Cellular Assays
7.2.1 In-Vitro Toxicology Market For Cellular Assay, 2020 - 2032
7.2.2 Live Cells
7.2.2.1 In-vitro toxicology market for live cells, 2020 - 2032
7.2.2.2 High throughput / high content screening
7.2.2.2.1 High throughput / high content screening market for live cell-based in-vitro toxicology testing, 2020 - 2032
7.2.2.3 Molecular imaging
7.2.2.3.1 Molecular imaging market for live cell-based in-vitro toxicology testing, 2020 - 2032
7.2.2.3.2 Confocal microscopy
7.2.2.3.2.1 Confocal microscopy market for live cell-based in-vitro toxicology testing, 2020 - 2032
7.2.2.3.3 Other molecular imaging technique
7.2.2.3.3.1 Other molecular imaging technique market for live cell-based in-vitro toxicology testing, 2020 - 2032
7.2.2.4 Others
7.2.2.4.1 Live cell-based in-vitro toxicology testing market for other technologies, 2020 - 2032
7.2.3 Fixed Cells
7.2.3.1 Fixed cell-based in-vitro toxicology testing market, 2020 - 2032
7.3 Biochemical Assays
7.3.1 Biochemical Assays Market For In Vitro Toxicology Testing, 2020 - 2032
7.4 In Silico
7.4.1 In Silico Assays Market For In Vitro Toxicology Testing, 2020 - 2032
7.5 Ex Vivo
7.5.1 Ex Vivo Assays Market For In Vitro Toxicology Testing, 2020 - 2032
Chapter 8 In-Vitro Toxicology Testing Market: Regional Business Analysis
8.1 In-Vitro Toxicology Testing Market: Regional Movement Analysis
8.2 North America
8.2.1 Swot Analysis
8.2.1.1 North America In-Vitro Toxicology Testing Market Estimates And Forecast, 2020 - 2032
8.2.2 U.S.
8.2.2.1 Key Country Dynamics
8.2.2.2 Competitive Scenario
8.2.2.3 U.S. In-Vitro Toxicology Testing Market, 2020 - 2032
8.2.3 Canada
8.2.3.1 Key Country Dynamics
8.2.3.2 Competitive Scenario
8.2.3.3 Canada In-Vitro Toxicology Testing Market, 2020 - 2032
8.3 Europe
8.3.1 Swot Analysis
8.3.1.1 Europe In-Vitro Toxicology Testing Market Estimates And Forecast, 2020 - 2032
8.3.2 Germany
8.3.2.1 Key Country Dynamics
8.3.2.2 Competitive Scenario
8.3.2.3 Germany In-Vitro Toxicology Testing Market, 2020 - 2032
8.3.3 U.K.
8.3.3.1 Key Country Dynamics
8.3.3.2 Competitive Scenario
8.3.3.3 U.K. In-Vitro Toxicology Testing Market, 2020 - 2032
8.3.4 France
8.3.4.1 Key Country Dynamics
8.3.4.2 Competitive Scenario
8.3.4.3 France In-Vitro Toxicology Testing Market, 2020 - 2032
8.3.5 Italy
8.3.5.1 Key Country Dynamics
8.3.5.2 Competitive Scenario
8.3.5.3 Italy In-Vitro Toxicology Testing Market, 2020 - 2032
8.3.6 Spain
8.3.6.1 Key Country Dynamics
8.3.6.2 Competitive Scenario
8.3.6.3 Spain In-Vitro Toxicology Testing Market, 2020 - 2032
8.3.7 Denmark
8.3.7.1 Key Country Dynamics
8.3.7.2 Competitive Scenario
8.3.7.3 Denmark In-Vitro Toxicology Testing Market, 2020 - 2032
8.3.8 Sweden
8.3.8.1 Key Country Dynamics
8.3.8.2 Competitive Scenario
8.3.8.3 Sweden In-Vitro Toxicology Testing Market, 2020 - 2032
8.3.9 Norway
8.3.9.1 Key Country Dynamics
8.3.9.2 Competitive Scenario
8.3.9.3 Norway In-Vitro Toxicology Testing Market, 2020 - 2032
8.4 Asia Pacific
8.4.1 Swot Analysis
8.4.1.1 Asia Pacific In-Vitro Toxicology Testing Market Estimates And Forecast, 2020 - 2032
8.4.2 Japan
8.4.2.1 Key Country Dynamics
8.4.2.2 Competitive Scenario
8.4.2.3 Japan In-Vitro Toxicology Testing Market, 2020 - 2032
8.4.3 China
8.4.3.1 Key Country Dynamics
8.4.3.2 Competitive Scenario
8.4.3.3 China In-Vitro Toxicology Testing Market, 2020 - 2032
8.4.4 India
8.4.4.1 Key Country Dynamics
8.4.4.2 Competitive Scenario
8.4.4.3 India In-Vitro Toxicology Testing Market, 2020 - 2032
8.4.5 Australia
8.4.5.1 Key Country Dynamics
8.4.5.2 Competitive Scenario
8.4.5.3 Australia In-Vitro Toxicology Testing Market, 2020 - 2032
8.4.6 Thailand
8.4.6.1 Key Country Dynamics
8.4.6.2 Competitive Scenario
8.4.6.3 Thailand In-Vitro Toxicology Testing Market, 2020 - 2032
8.4.7 South Korea
8.4.7.1 Key Country Dynamics
8.4.7.2 Competitive Scenario
8.4.7.3 South Korea In-Vitro Toxicology Testing Market, 2020 - 2032
8.5 Latin America
8.5.1 Swot Analysis
8.5.1.1 Latin America In-Vitro Toxicology Testing Market Estimates And Forecast, 2020 - 2032
8.5.2 Brazil
8.5.2.1 Key Country Dynamics
8.5.2.2 Competitive Scenario
8.5.2.3 Brazil In-Vitro Toxicology Testing Market, 2020 - 2032
8.5.3 Mexico
8.5.3.1 Key Country Dynamics
8.5.3.2 Competitive Scenario
8.5.3.3 Mexico In-Vitro Toxicology Testing Market, 2020 - 2032
8.5.4 Argentina
8.5.4.1 Key Country Dynamics
8.5.4.2 Competitive Scenario
8.5.4.3 Argentina In-Vitro Toxicology Testing Market, 2020 - 2032
8.6 Middle East & Africa (MEA)
8.6.1 Swot Analysis
8.6.1.1 MEA In-Vitro Toxicology Testing Market Estimates And Forecast, 2020 - 2032
8.6.2 South Africa
8.6.2.1 Key Country Dynamics
8.6.2.2 Competitive Scenario
8.6.2.3 South Africa In-Vitro Toxicology Testing Market, 2020 - 2032
8.6.3 Saudi Arabia
8.6.3.1 Key Country Dynamics
8.6.3.2 Competitive Scenario
8.6.3.3 Saudi Arabia In-Vitro Toxicology Testing Market, 2020-2032
8.6.4 UAE
8.6.4.1 Key Country Dynamics
8.6.4.2 Competitive Scenario
8.6.4.3 UAE In-Vitro Toxicology Testing Market, 2020-2032
8.6.5 Kuwait
8.6.5.1 Key Country Dynamics
8.6.5.2 Competitive Scenario
8.6.5.3 Kuwait In-Vitro Toxicology Testing Market, 2020-2032
Chapter 9 Competitive Landscape
9.1 Participant’s Overview
9.1.1 Charles River Laboratories International, Inc.
9.1.2 Thermo Fisher Scientific, Inc.
9.1.3 Abbott Laboratories
9.1.4 Sgs S.A.
9.1.5 Laboratory Corporation Of America Holdings
9.1.6 Merck Kgaa
9.1.7 Eurofins Scientific
9.1.8 Evotec S.E.
9.1.9 Agilent Technolgies, Inc.
9.1.10 Quest Diagnostics Incorporated
9.1.11 Danaher Corporation
9.1.12 Bio-Rad Laboratories, Inc.
9.1.13 Catalent, Inc.
9.1.14 Bioivt
9.1.15 Gentronix
9.2 Financial Performance
9.3 Participant Categorization
9.3.1 Market Leaders
9.3.1.1 In-Vitro Toxicology Testing Market Share Analysis, 2022
9.3.2 Strategy Mapping
9.3.2.1 Expansion
9.3.2.2 Acquisition
9.3.2.3 Collaborations
9.3.2.4 Product/service launch
9.3.2.5 Partnerships
9.3.2.6 Others
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers